Impact ledger
Intellia Therapeutics, Inc. (NTLA): the developments shaping its investment case
Follow the evidence affecting Intellia Therapeutics, Inc.'s demand outlook. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.
Test assumptions, examine opportunities, and save your research.
Material developments
Evidence affecting valuation assumptions
Each entry names the assumption the evidence touches and how the evidence reads. Direction describes the business mechanism, not a stock-price conclusion.
| Date | Assumption | Direction | Interpretation |
|---|---|---|---|
| 2026-06-15 | revenue | Bullish | Positive Phase 3 HAELO trial results for lonvo-z and initiated rolling BLA submission support potential U.S. launch in 1H 2027. |
| 2026-06-15 | revenue | Bullish | Positive Phase 3 HAELO trial results for lonvo-z and initiated rolling BLA submission support future commercial launch in 2027. |
Event impact log
5 events mapped to NTLA since 2026-09-09. Evidence through 2026-09-12.
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-09-12 | Cellectis Schedules September 14 Business and CAR T Pipeline Update | Second-order effect through sector sentiment. Cellectis's update on gene editing and CAR T development could influence investor perception of the broader gene editing and cell therapy space. | watch | 1-5d | 0.30 |
| 2026-09-09 | CRISPR Therapeutics Expands Casgevy Pediatric Label After 78% QoQ Sales Jump | Indirect positive sentiment for gene editing technology and platform validation. Potential for increased investor interest in the broader gene editing space. | Bullish | 3-12m | 0.40 |
| 2026-09-09 | CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76M | Positive read-through for the broader CRISPR gene editing platform and validation of the technology's commercial viability. | Bullish | 3-12m | 0.30 |
| 2026-09-09 | FDA Approves Label Expansion for CRISPR Therapeutics Gene Therapy Casgevy | Positive sentiment spillover for CRISPR-based gene editing companies, potentially increasing investor confidence in the technology platform. | Bullish | 1-3m | 0.30 |
| 2026-09-09 | CRISPR Therapeutics reports 78 percent QoQ Casgevy sales growth to $76M | Positive sentiment spillover for gene editing technology and platform validation | Bullish | 3-12m | 0.40 |
Continue this research
Build your Intellia Therapeutics, Inc. investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.
This ledger is regenerated from Market Ontology's public event pipeline. View the NTLA entity page →